Paracetamol, Pan D, among 53 drugs fail drug regulator’s quality test; raises safety concerns

0

The central body CDSCO declared paracetamol, Pan D and 51 other drugs as ‘not of standard quality’ in its monthly quality check report.

original-p_1727279677923_1727279678088

Over 50 drugs declared 'not of standard quality' by central body (Yves Herman / REUTERS)

WhatsApp Channel Join Now
Telegram Group Join Now
Instagram Join Now

The Central Drugs Standard Control Organisation (CDSCO) declared over 50 drugs, including paracetamol, Pan D and calcium supplements, as ‘not of standard quality’ in its recent monthly report, raising safety concerns over their use.

In its August 2024 report, the central drug regulator placed paracetamol, vitamin D and calcium supplements, hypertension medicines and some anti-diabetes tablets in the “not of standard quality (NSQ alert)” category. NSQ alerts are generated from random monthly sampling done by state drug authorities.

The medicines that failed the quality check include vitamin C and D3 tablets, Shelcal, vitamin B complex, vitamin C softgels, anti-acid Pan-D, paracetamol tablets (IP 500 mg), anti-diabetic drug Glimepiride and hypertension drug Telmisartan.

These products were manufactured by several companies, including Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Ltd (HAL), Karnataka Antibiotics and Pharmaceuticals Ltd, Pure & Cure Healthcare and Meg Lifesciences.

Metronidazole, a commonly used treatment for stomach infections produced by HAL, also failed the quality test. Similarly, calcium and vitamin D3 supplement Shelcal has been marked in the NSQ alert category.

A drug-testing laboratory in Kolkata found antibiotics such as Clavam 625 and Pan D to be fake. Cepodem XP 50 Dry Suspension, a common infection drug used for children, was also tested in the same lab and was flagged by the CDSCO for failing the quality test.

The central drug regulator released two lists – one containing 48 drugs that failed the quality test and the other containing 5 drugs in the NSG alert category, along with the response of their manufacturers.

“The genuine manufacturer (as per label claim) has informed that the suspect batch of the product is not manufactured by them and is a counterfeit drug. The product is considered counterfeit, however, this is subject to the outcome of the investigation,” reads the response of the drugmaker of Pulmosil.

In August this year, the CDSCO banned over 156 fixed dose drug combinations across the country for “potential risk to humans”.

Kumud Sharma

https://diarytimes.com/

Continuing the achievement of the journey of effectiveness and credibility of more than 10 years in the career of journalism, as a woman journalist, I am Serving as the founder, promoter and editor of DiaryTimes with the trust and support of all. My credible coverage may not have given a big shape to the numbers, but my journey presents articles that make you aware of the exact and meaningful situations of Himachal’s politics, ground issues related to the public, business, tourism and the difficult geographical conditions of the state and financial awareness. DiaryTimes, full of the experience of my precise editorial expertise, is awakening the flame of credible journalism among all of you, so that the eternal flame of meaningful change can be lit in the life of the people of the state and the atrocities being committed against the people can be brought to the fore, I am motivated for that. If even a small change comes with the power of my journalism and the whole world becomes a witness to that issues, then I will consider myself fortunate.

Leave a Reply

Your email address will not be published. Required fields are marked *